Blood test may help identify patients at risk for transthyretin amyloid cardiomyopathy

FHS
July 29, 2023
1:21 am

A new multi-center study led by doctors at Boston Medical Center and Columbia University found that having a genetic variant in the prealbumin gene alone is not sufficient for diagnosis of transthyretin amyloid cardiomyopathy in older Black patients.

Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-9574?

AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.

April 17, 2024

New study identifies key protein biomarkers for early detection of pancreatic cancer

Study used a Mendelian randomization approach to identify REG1A and REG1B as potential biomarkers for early detection of pancreatic cancer, showing their causal effects and

May 20, 2024

Achieve Life Sciences nabs $124M; Pierre Fabre buys pan-RAF program from Kinnate

Plus, news about Tarsus Pharmaceuticals, Humacyte, Stemcell Technologies and SQZ Biotechnologies: Achieve Life Sciences raises $124M, details plans for NDA: The company plans to submit

March 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.